Gilead Sciences Inc. (GILD)

65.35
NASDAQ : Health Technology
Prev Close 65.30
Day Low/High 65.00 / 65.88
52 Wk Low/High 60.32 / 76.44
Avg Volume 5.96M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 82.70B
EPS 4.20
P/E Ratio 9.16
Div & Yield 2.52 (3.81%)

Latest News

Gilead Sciences To Release Third Quarter 2019 Financial Results On Thursday, October 24, 2019

Gilead Sciences To Release Third Quarter 2019 Financial Results On Thursday, October 24, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes.

Protect the Football : Cramer's 'Mad Money' Recap (Tuesday 10/8/19)

Protect the Football : Cramer's 'Mad Money' Recap (Tuesday 10/8/19)

Cramer says with these unrelenting trade pressures, investors shouldn't do anything outrageous, anything fancy. They should hold tight and wait for when China isn't so in the balance.

Roku, Gilead Sciences, HEXO: 'Mad Money' Lightning Round

Roku, Gilead Sciences, HEXO: 'Mad Money' Lightning Round

Jim Cramer takes a look at Roku, Gilead Sciences, HEXO, Rambus, Canopy Growth, Kroger, Costco.

Gilead Sciences Submits New Drug Application For Filgotinib For The Treatment Of Adults With Rheumatoid Arthritis In Japan

Gilead Sciences Submits New Drug Application For Filgotinib For The Treatment Of Adults With Rheumatoid Arthritis In Japan

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has been submitted to the Japanese...

Gilead Sciences Appoints Merdad Parsey, MD, PhD As Chief Medical Officer

Gilead Sciences Appoints Merdad Parsey, MD, PhD As Chief Medical Officer

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1.

Gilead Presents New Data From The Company's HIV Clinical Development Program And Latest Findings On The Impact Of HIV Pre-exposure Prophylaxis (PrEP) At IDWeek 2019

Gilead Presents New Data From The Company's HIV Clinical Development Program And Latest Findings On The Impact Of HIV Pre-exposure Prophylaxis (PrEP) At IDWeek 2019

Gilead Sciences, Inc. (NASDAQ: GILD) today announced important findings from the DISCOVER trial evaluating Descovy ® (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP), showing significant...

U.S. Food And Drug Administration Approves Descovy® For HIV Pre-Exposure Prophylaxis (PrEP)

U.S. Food And Drug Administration Approves Descovy® For HIV Pre-Exposure Prophylaxis (PrEP)

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.

Gilead Sciences And The Elton John AIDS Foundation Launch RADIAN Initiative To Address HIV In Eastern Europe And Central Asia (EECA)

Gilead Sciences And The Elton John AIDS Foundation Launch RADIAN Initiative To Address HIV In Eastern Europe And Central Asia (EECA)

Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London.

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Tuesday, September 10

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Tuesday, September 10

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10 at 10:00 a.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Gilead And Galapagos Complete Closing Of Their Transformative Research And Development Collaboration

Gilead And Galapagos Complete Closing Of Their Transformative Research And Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019.

European Medicines Agency Validates Marketing Application For Filgotinib For The Treatment Of Rheumatoid Arthritis

European Medicines Agency Validates Marketing Application For Filgotinib For The Treatment Of Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with...

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) For Treatment Of HIV-1 Infection

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) For Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy ® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen...

Gilead Sciences Statement On U.S. Food And Drug Administration Advisory Committee's Recommendation On Descovy For PrEP™

Gilead Sciences Statement On U.S. Food And Drug Administration Advisory Committee's Recommendation On Descovy For PrEP™

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the Antimicrobial Drugs Advisory Committee (AMDAC) of the U.

(Photo: Business Wire)

(Photo: Business Wire)

Gilead Sciences Canada, Inc. (Gilead Canada) today announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a...

Gilead Sciences Announces Third Quarter 2019 Dividend

Gilead Sciences Announces Third Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2019 Financial Results

Gilead Sciences Announces Second Quarter 2019 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2019.

Biggest Earnings Tuesday: Apple, Procter & Gamble, Under Armour and More

Biggest Earnings Tuesday: Apple, Procter & Gamble, Under Armour and More

Brace yourself. It's a busy earnings day! Here's list of key companies to watch for on Tuesday, July 30, 2019.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Small Caps Stage Comeback

But we’ve seen it before: They spike only to fall back down.

Gilead Announces Latest Data In Ongoing HIV Cure Research Program

Gilead Announces Latest Data In Ongoing HIV Cure Research Program

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program.

Gilead Presents New Findings On Profile Of Descovy® For Potential Use As HIV Pre-exposure Prophylaxis Compared With Truvada®

Gilead Presents New Findings On Profile Of Descovy® For Potential Use As HIV Pre-exposure Prophylaxis Compared With Truvada®

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP).

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Gilead Presents New Data On Biktarvy® For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance

Gilead Presents New Data On Biktarvy® For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials - a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a...

Gilead Presents Proof-of-Concept Data For GS-6207, A First-in-Class Capsid Inhibitor, In People Living With HIV

Gilead Presents Proof-of-Concept Data For GS-6207, A First-in-Class Capsid Inhibitor, In People Living With HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function.

Gilead Sciences Licenses Respiratory And Herpes Antiviral Research Programs From Novartis

Gilead Sciences Licenses Respiratory And Herpes Antiviral Research Programs From Novartis

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

Gilead To Present New Data On HIV Prevention, Treatment And Cure Research At IAS 2019

Gilead To Present New Data On HIV Prevention, Treatment And Cure Research At IAS 2019

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that new data from the company's HIV research and development programs will be presented at the 10 th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City from July...

Gilead Sciences Announces Changes To Senior Leadership Team

Gilead Sciences Announces Changes To Senior Leadership Team

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company's senior leadership team.

TheStreet Quant Rating: C+ (Hold)